Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 |
Tel: | N/A |
Website: | https://www.aprea.com |
IR: | See website |
Key People | ||
Oren Gilad President, Chief Executive Officer, Director | John P. Hamill Chief Financial Officer, Senior Vice President, Secretary |
Business Overview |
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company's advanced synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) a kinase that plays a critical role in DNA damage response (DDR). ATR and Checkpoint Kinase 1 are critical DDR kinases that prevent the collapse of replication forks into DNA double-strand breaks. It has completed all IND enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and received United States Food and Drug Administration (FDA) clearance of its IND. It has an early-stage program that is in the lead optimization stage, for an undisclosed DDR target. The Company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. |
Financial Overview |
For the fiscal year ended 31 December 2023, Aprea Therapeutics Inc revenues increased from $0K to $583K. Net loss decreased 87% to $14.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects PHARMACEUTICAL PREPARATIONS segment loss decrease of 86% to $15.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$67.99 to -$3.95. |
Employees: | 7 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $10.17M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.58M as of Dec 31, 2023 |
EBITDA (TTM): | -$15.46M as of Dec 31, 2023 |
Net annual income (TTM): | -$14.29M as of Dec 31, 2023 |
Free cash flow (TTM): | -$12.18M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 5,430,215 as of Mar 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |